http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-1218649-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_da54f7ebbd2d9d8a82f92aca4d1b4e48 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C405-0041 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C405-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C405-0016 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-045 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C35-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-557 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C401-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C405-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C67-00 |
| filingDate | 1982-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1987-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a7f309e46f1dd9fe6033fc7eb6f5675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb7587a1a23b5049edea8184417123c3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58c2b760837325ed3292e0782a515f4a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3cf93d6205cc6ebd813d55c9abece003 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14dc9915b4ff2251417f2097a6311db6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a079d6172a1fb1d237e73b48c4d11e63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9acd841e9338472489309581db46dfa |
| publicationDate | 1987-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-1218649-A |
| titleOfInvention | .delta..sup.8,.sup.9-prostaglandin derivatives, process for their manufacture and their use as medicaments |
| abstract | ABSTRACT OF THE DISCLOSURE Novel .DELTA.8,9-prostane derivatives of the general for-mula I (I) in which R1 represents a -CH2OH group, or represents a group of the formula in which R2 represents a hydrogen atom, alkyl group with 1 to 4 carbon atoms, or represents a group of the formula , in which R3 represents a C1-C10-acyl, methyl sulphonyl or isopropyl sulphonyl group or represents R2, A represents a -CH2-CH2- group or a cis-CH=CH-group, B represents a -CH2-CH2- group, a trans-CH=CH- group or a -C?C- group, W represents a free or functionally modified hydroxymethylene group or a free or functionally modified group, the hydroxyl group in each group being in the .alpha.-or .beta.-position, D and E together represent a direct bond or D represents a straight-chain or branched-chain bivalent ali-phatic hydrocarbon group containing up to 10 carbon atoms which may be substituted by at least one fluorine atom and E represents an oxygen or sulphur atom, a direct bond, a-C?C-group or a group of the formula -CR6=CR7- in which R6 and R7 have different meanings and each represents a hydrogen atom, a chlorine atom or an alkyl group having 1 to 6 carbon atoms, R4 represents a free or functionally modified hydroxyl group, and R5 represents a straight chain or branched, saturated or unsaturated alkyl group with 1 to 6 carbon atoms, a benzyl group or when E is oxygen a phenyl group produced that D-E-R5 is other than n- pentyl, when W is -CHOH, Bis trans-CH=CH-, R4 is OH, A is cis-CH=CH- and R1 is -COOCH3 or a physiologically toler-able salt with a base of such a compound in which R1 represents a group of the formula in which R2 represents a hydrogen atom. The .DELTA.8,9-prostane derivatives and pharmaceu-tically acceptablesalts thereof have inter alia a luteolytic and abortive activity and may accordingly be made up into pharma-ceutical preparations with suitable carriers. |
| priorityDate | 1981-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 165.